Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors

It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hepatocellular carcinoma 2021-01, Vol.8, p.263-270
Main Authors: Chen, Li, Liu, Zhi-Xing, Bi, Qiu-Chen, Zhao, Jun, Liang, Qing-Rong, Tang, Qun
Format: Article
Language:English
Subjects:
Abdomen
Ablation
Apoptosis
Biopsy
Cancer therapies
Cell division
Cell proliferation
Chemotherapy
combined therapy
Correlation analysis
Cytotoxicity
Dehydration
Drug dosages
Ethanol
Iodine
Kruskal-Wallis test
Laboratory animals
Liver cancer
Necrosis
new indication
Original Research
Paclitaxel
Peat
percutaneous ethanol ablation therapy
Rabbits
Scanners
Sectioning
Tumors
Ultrasonic imaging
Ultrasound
vx2 liver cancer model
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It is difficult to achieve whole tumor ablation using percutaneous ethanol ablation therapy (PEAT) due to the limited diffusion of ethanol. To determine whether chemotherapy can be an adjuvant therapy to benefit PEAT, we investigated ultrasound-guided percutaneous ethanol-paclitaxel combined therapy (PEPCT) of VX2 carcinoma, a rabbit liver cancer model. A six-arm study was designed to quantify the correlation between paclitaxel (PTX) dose and tumor necrosis or cell proliferation, including sham group (2 mL saline, n=6), incremented dose of PTX (0, 12.5, 25, 37.5 mg) in 2.0 mL ethanol (n=6) and a conventional PEAT group (n=6) as comparison. The test was followed by contrast-enhanced ultrasonic (CEUS) before 7-day sacrifice, tumor harvest, and sectioning. Tumor necrosis ratio was radiologically and histologically quantified; modified proliferation index ( -PI) was proposed to quantify the PTX's pharmacological effects. A linear regression model was set to correlate the PTX dose with tumor necrosis ratio or cell proliferation index. The difference of radiological, histological necrosis ratio (HNR) and modified PI in six groups was analyzed via Kruskal-Wallis -test, Welch analysis of variance and one-way ANOVA. Incremental increases of PTX (0, 12.5, 25, 37.5 mg) correlated with greater fraction of tumor necrosis (R = 0.946, P
ISSN:2253-5969
2253-5969
DOI:10.2147/JHC.S301083